The final analysis of the HERceptin Adjuvant (HERA) trial, with a median follow-up of 11 years, suggests that administration of trastuzumab for one year after chemotherapy in individuals diagnosed with HER2-positive early breast cancer demonstrates significant improvement in long-term disease-free survival (DFS) [5]. Here, ERBB2 is linked to breast carcinoma.